New! Sign up for our free email newsletter.

Lymphoma News

March 19, 2024

Top Headlines

 

Scientists may have found a way around the limitations of engineered T cells by borrowing a few tricks from cancer itself. By studying mutations in malignant T cells that cause lymphoma, they zeroed in on one that imparted exceptional potency to ...
Researchers have identified a novel pharmaceutical compound that successfully kills leukemia and lymphoma cancer cells, potentially paving the way for new forms of ...
Early results from a Phase I clinical trial of AT101, a new CAR T cell therapy that uses a distinct binding mechanism to target CD19, show a 100 percent complete response (CR) rate at the higher dose ...
Immunotherapies that target the CD20 antigen have revolutionized how patients with a variety of blood cancers and hematologic disorders have been treated. However, many patients develop resistance to ...

Latest Headlines

updated 9:43am EDT

Earlier Headlines

 

A research team has discovered a highly potent biomarker for clinical response to CAR-T cell therapy, describing the prerequisites for optimal use of this novel therapy for lymphoma treatment. The ...

Researchers have demonstrated that people suffering from blood cancer have a good immune response to COVID-19 vaccinations. Vaccination protects patients with B-cell lymphoma and multiple myeloma ...

A form of blood cancer known as mantle cell lymphoma is critically dependent on a protein that coordinates gene expression, such that blocking its activity with an experimental drug dramatically ...

A panel of investigational monoclonal antibodies (mAbs) targeting different sites of the Epstein-Barr virus (EBV) blocked infection when tested in human cells in a laboratory setting. Moreover, one ...

Scientists have completed the largest study of families affected by Hodgkin lymphoma and identified novel variants linked to cancer ...

An engineer has found a way to determine which patients are likely to respond to #CAR T-cell therapy, saving precious time in treating #lymphoma, which is most responsive to this form of ...

A study has found that the addition of brentuximab vedotin to standard chemotherapy treatment improves overall survival in patients with Hodgkin Lymphoma, when compared to the current standard of ...

There is considerable variation in the management of mantle cell lymphoma across different clinical settings, and some strategies do not always conform with what might be expected, according to a ...

A new study shows that treatment with an immunity boosting protein called interleukin 7 (IL-7) after an infusion of genetically modified T cells causes the cancer-fighting CAR-T cells to grow in ...

Researchers have discovered that the interferon gamma receptor (IFNgR) signaling pathway is critical for susceptibility of glioblastoma tumors to killing by CAR T-cell ...

Combination chemoimmunotherapy with the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib demonstrated improved progression-free survival over standard chemoimmunotherapy for previously ...

DNA mutations are essential to the rapid development of an array of antibody-producing immune cells called B cells that collectively can recognize a vast number of specific targets. But this process ...

In early research, the oral medication zanubrutinib was found to help most patients with a slow-growing type of cancer known as marginal zone ...

A study investigates the reasons for decreasing remission rates for patients with non-Hodgkin lymphoma treated with chimeric antigen receptor-T cell therapy (CAR-T cell ...

Researchers identify gene expression signatures in different types of lymph nodes cells that play an active role in the development of ...

A recent study followed 515 patients with varying cancers. The goal was to evaluate if patients had an immune response to the Moderna mRNA-1273 vaccine and if that response differed by diagnosis and ...

Researchers have shared a comprehensive multiomics study from a rare cohort of 56 patients with transformed CTCL and identified several genomic alterations and oncogenic programs that may be ...

There are myriad reasons why cancers develop. By studying genes which are altered in people with lymphoma, a multidisciplinary team of researchers has identified a key mechanism involved in disease ...

Aggressive and relatively common lymphomas called diffuse large B cell lymphomas (DLBCLs) have a critical metabolic vulnerability that can be exploited to trick these cancers into starving ...

Driving up the immune response at the site of a cancer tumor with nanotechnology may help enhance immunotherapy treatments in advanced stages of the disease, new research in mice ...

Monday, January 9, 2023

Thursday, December 22, 2022

Tuesday, November 22, 2022

Thursday, October 27, 2022

Thursday, September 8, 2022

Wednesday, August 24, 2022

Thursday, July 14, 2022

Tuesday, June 28, 2022

Tuesday, June 14, 2022

Thursday, June 9, 2022

Friday, June 3, 2022

Wednesday, May 25, 2022

Friday, May 13, 2022

Thursday, May 12, 2022

Thursday, April 28, 2022

Thursday, March 10, 2022

Monday, February 28, 2022

Wednesday, January 12, 2022

Monday, January 3, 2022

Tuesday, December 14, 2021

Thursday, November 4, 2021

Wednesday, October 13, 2021

Friday, September 3, 2021

Tuesday, August 24, 2021

Thursday, July 1, 2021

Wednesday, April 14, 2021

Sunday, April 11, 2021